PHARMACOGENETICS, POPULATION STRUCTURE AND ADMIXTURE Guilherme Suarez-Kurtz Rio de Janeiro - Brazil Guilherme Suarez-Kurtz Rio de Janeiro - Brazil RS-ICSU-IAP.

Slides:



Advertisements
Similar presentations
ACCF/AHA Clopidogrel Clinical Alert: Approaches to the FDA “Boxed Warning” A Report of the American College of Cardiology Foundation Task Force on Clinical.
Advertisements

CZ5225 Methods in Computational Biology Lecture 9: Pharmacogenetics and individual variation of drug response CZ5225 Methods in Computational Biology.
Pavel Tarlykov, PhD General Genetics LTD Astana, Kazakhstan Raleigh, 2014.
Pharmacogenetics and the Management of Breast Cancer: Optimization of Tamoxifen Therapy Mark E. Sobel, M.D., Ph.D. Executive Officer American Society for.
1 Pharmacogenetics: Improvement of Existing Drug Treatments Zhou Yan-Qiong.
Methods and challenges in the analysis of admixed human genomes Simon Gravel Stanford University.
Genomics, Bioinformatics & Medicine
Andrew To Cardiologist North Shore Hospital, Auckland, New Zealand June 2014 Cardiovascular Health in Chinese New Zealanders.
Introduction to Population Stratification. Standard definition of confounding A confounder is 1. Associated with the exposure in the study base 2. Associated.
Revision of unit 1 8th grade. What is the nationality of the USA?
PHAR 751 Pharmacogenomics Sarah Brown, Pharm.D. Pharmacy Practice Resident Asante Health System
Human Genetics, part II Liisa Kauppi (Keeney lab) Human populations: origins Implications of population history for disease mapping.
Pharmacogenetics Definitions – Pharmacogenetics: single gene differences among population groups and the effects on pharmacodynamics. – Pharmacegenomics:
Computational research for medical discovery at Boston College Biology Gabor T. Marth Boston College Department of Biology
Bioethics Concerns in Regulating Large DNA Collections: The Israeli Experience David Gurwitz National Laboratory for the Genetics of Israeli Populations.
A single-nucleotide polymorphism tagging set for human drug metabolism and transport Kourosh R Ahmadi, Mike E Weale, Zhengyu Y Xue, Nicole Soranzo, David.
Continuity of Change: Where We Have Come From, Where We Are Going New Orleans, LA June 5 th – June 9 th, 2011 Bruce Cohen, Malena Hood, and James K. West.
New Insights on Warfarin: How CYP 2C9 & VKORC1 Information May Improve Benefit-Risk Ratio Brian F. Gage, MD, MSc Associate Professor of Medicine, Washington.
Pharmacogenetics & Pharmacogenomics Personalized Medicine.
Lecture Three The (Racial) History of the US. Who is American? When you hear the word “American” who do you think of?  Describe this person. Why do we.
PHAR 751 Pharmacogenomics
Regional Concentrations of Ethnicities Where does the clustering of ethnicities occur? Where are African-Americans clustered? Hispanics? Asian- Americans?
Genetic Association Study Principles: Andrew C. Heath.
Challenges to drug design Did you know? Over 2 million people are hospitalized each year for adverse reactions to prescription drugs. Over 2 million.
Admixture Mapping Controlled Crosses Are Often Used to Determine the Genetic Basis of Differences Between Populations. When controlled crosses are not.
Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? by Ching-Hon Pui, Charles G. Mullighan, William E. Evans, and Mary.
Pharmacogenetics/Pharmacogenomics. Outline Introduction  Differential drug efficacy  People react differently to drugs Why does drug response vary?
Number of Papers with Health Disparities in the Title
The Evaluation of CYP2D6, CYP2C9 and CYP2C19 Polymorphisms for Personalized Medicine in Psychiatry Patients Ebru DÜNDAR YENILMEZ1, Onur KARAYTUG2, Lut.
Pharmacogenetics: Implications of race and ethnicity on defining genetic profiles for personalized medicine  Victor E. Ortega, MD, Deborah A. Meyers,
Pharmacogenomics Identification of genes variants that influence drug effects. Is it possible to predict the effect of a drug in a certain patient? Pharmacogenetics/genomics.
The Evaluation of CYP2D6, CYP2C9 and CYP2C19 Polymorphisms for Personalized Medicine in Physiciatry Patients Ebru DUNDAR YENILMEZ1, Onur KARAYTUG2, Lut.
Enzymes involved in drug metabolism
How Closely Do California’s RN Graduates Reflect the State’s Diversity? This chart compares the racial and ethnic composition of California’s general population.
Enrollees by Race and Ethnicity in U.S. Dental Schools, 2000 to 2009
Applicants by Race and Ethnicity in U.S. Dental Schools,
How Closely Do Ohio’s RN Graduates Reflect the State’s Diversity?
How Closely Do Georgia’s RN Graduates Reflect the State’s Diversity?
Race, Ethnicity, Nationality
How Closely Do Washington’s RN Graduates Reflect the State’s Diversity? This chart compares the racial and ethnic composition of Washington’s general.
How Closely Do Washington’s RN Graduates Reflect the State’s Diversity? This chart compares the racial and ethnic composition of Washington’s general population.
African American.
Applicants by Race and Ethnicity in U.S. Dental Schools, 2010 to 2016
How Closely Do New Mexico’s RN Graduates Reflect the State’s Diversity? This chart compares the racial and ethnic composition of New Mexico’s general population.
How Closely Do New Mexico’s RN Graduates Reflect the State’s Diversity? This chart compares the racial and ethnic composition of New Mexico’s general.
How Closely Do California’s RN Graduates Reflect the State’s Diversity? This chart compares the racial and ethnic composition of California’s general.
How Closely Do Oregon’s RN Graduates Reflect the State’s Diversity?
How Closely Do New York’s RN Graduates Reflect the State’s Diversity?
How Closely Do Virginia’s RN Graduates Reflect the State’s Diversity?
Enrollees by Race and Ethnicity in U.S. Dental Schools, 2000 to 2015
Applicants by Race and Ethnicity in U.S. Dental Schools, 2010 to 2018
Total Faculty by Race and Ethnicity,
Applicants by Race and Ethnicity in U.S. Dental Schools, 2000 to 2009
How Closely Do New York’s RN Graduates Reflect the State’s Diversity?
How Closely Do Florida’s RN Graduates Reflect the State’s Diversity?
Human Population Genetic Structure and Inference of Group Membership
How Closely Do Georgia’s RN Graduates Reflect the State’s Diversity?
How Closely Do Georgia’s RN Graduates Reflect the State’s Diversity?
How Closely Do Washington’s RN Graduates Reflect the State’s Diversity? This chart compares the racial and ethnic composition of Washington’s general population.
Mestizos and Mulattos.
How Closely Do Oregon’s RN Graduates Reflect the State’s Diversity?
How Closely Do Florida’s RN Graduates Reflect the State’s Diversity?
How Closely Do Virginia’s RN Graduates Reflect the State’s Diversity?
LD unit maps of the NIDDM1 region.
How Closely Do California’s RN Graduates Reflect the State’s Diversity? This chart compares the racial and ethnic composition of California’s general population.
How Closely Do New Mexico’s RN Graduates Reflect the State’s Diversity? This chart compares the racial and ethnic composition of New Mexico’s general population.
How Closely Do Maine’s RN Graduates Reflect the State’s Diversity?
How Closely Do Florida’s RN Graduates Reflect the State’s Diversity?
How Closely Do New York’s RN Graduates Reflect the State’s Diversity?
Pharmacogenomics Identification of genes variants that influence drug effects. Is it possible to predict the effect of a drug in a certain patient? Pharmacogenetics/genomics.
Presentation transcript:

PHARMACOGENETICS, POPULATION STRUCTURE AND ADMIXTURE Guilherme Suarez-Kurtz Rio de Janeiro - Brazil Guilherme Suarez-Kurtz Rio de Janeiro - Brazil RS-ICSU-IAP 2006

Pharmacogenetics deals with drug responses (therapeutic or adverse) and their modification by hereditary factors.

P H A R M A C O G E N E T I C S P H A R M A C O G E N I C S Pharmacogenomics is pharmacogenetics with two SNPs O M

one drug/one dose fits all THE CURRENT PARADIGM

THE PHARMACOGENETICS PROMISE personalised therapy ”paradigm-disrupting”

PHARMACOGENETIC DATABASES Population frequencies of many polymorphic genes of pharmacogenetic interest depend on race or ethnic specificity. Information about ethnic specificity has become an integral part of pharmacogenetic research.

DRUG ACTIVE/inactive metabolite Phase I Cytochrome P450 (CYP) DRUG and XENOBIOTIC METABOLISM Phase II Glutathione-S-transferases (GST) INACTIVE metabolite

Continental populations

Population stratification in Singapore Chowbay et al., GSTM1-null Frequency (%) Indian Chinese Malay CYP3A5*1

Stratification : subpopulations

Data from Park et al., 2000; Tetlow et al., Genotype frequency (%) *A/*A *A/*B *B/*B GSTM3(6bp deletion) African Bantu White American African-American

Data from Park et al., 2000; Medeiros et al., 2004; Suarez-Kurtz et al., Genotype frequency (%) *A/*A *A/*B *B/*B GSTM3(6bp deletion) African Bantu Portuguese Black Brazilians

Stratification : admixture

GENETIC ADMIXTURE: the mixing of two or more genetically differentiated populations. “ Because of considerable genetic admixture in most human populations...” Nebert and Menon, Pharmacogenomics 2001

1500 ~ 2.5 M Amerindians ~ 0.5 M Portuguese ~ 4.5 M immigrants Portugal 1.7 M Italy 1.6 M Spain 0.7 M Germany 0.25 M ~ 3.6 M Enslaved Africans Sources of the tri-hybrid Brazilian population Suarez-Kurtz <

African ancestry index Brazilians in southeast rural area Parra et al., % 38% 53%

African ancestry index Brazilians in southeast rural area Parra et al., 2003

African ancestry index Brazilians in southeast rural area Parra et al., % 38% 53%

ADMIXTURE IN BRAZILIANS

Suarez-Kurtz et al., Clin Pharm Ther, 2005 based on 40 indel AIM set developed by Sergio D. J. Pena

European African Amerindian Self-declared WHITE Brazilians European African Amerindian Self-declared BLACK Brazilians Pena et al. 2006

Genotype frequency GSTM3*B/*B White Black African ancestry (%) 75

E. Parra et al., Nat Genet 2004 African-Caribbeans African-Americans Puerto Ricans Hispanics Mexicans *

a Jorde & Wooding, Nat Genet 2004, adapted from Bamshad et al., Am J Hum Genet 2003

Serre & Pääbo, 2004

African European Asian Oceanian Native American Serre & Pääbo, Genome Res 2004

Lamba et al. Clin Pharm Ther 2000 CYP2C19*2 CYP2C19*3 Worldwide gradients in CYP2C19 variant allele frequency

Surui

FREQUENCY DISTRIBUTION OF CYP2C9*5 Data from Dickman et al. (2001), Xie et al. (2003, and references therein), Llerena et al. (2004). PopulationCYP2C9*5 North-American African-American1.7 European-American0 Mexican-American0 African Beninese, Tanzanian Ethiopian0 European0 Asian0

> G > Glu G/C

Suarez-Kurtz et al. Clin Pharm Ther, % European 7.5% African 0.5% Amerindian mtDNA L3d

Father Mother

*5 *1 CYP2C9 alleles I W W I W “Race/ethnic” categorization/discrimination: appearance vs. descent